FDA keeps clinical hold in place on Larimar's lead drug with job cuts likely on the horizon
The FDA will extend its clinical hold on Larimar Therapeutics’ lead rare disease drug CTI-1601, asking for more data before it will reconsider the company’ …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
